IL2 and acute coronary syndrome: These data further support, although a posteriori, the selection of the 1.5 MIU d−1 dose for the phase 2b Low-Dose Interleukin 2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes (IVORY) trial43.